NASDAQ: CAPSCapstone Holding Corp Stock
$1.78+0.22 (+14.1%)
Updated Jul 29, 2025
CAPS Price
$1.78
Fair Value Price
N/A
Market Cap
$9.24M
52 Week Low
$1.30
52 Week High
$4.18
P/E
N/A
P/B
0.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.94
Operating Cash Flow
N/A
Beta
1.54
Next Earnings
Aug 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CAPS Overview
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CAPS's potential to beat the market
- CAPS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CAPS
RankedUnranked of 482
RankedUnranked of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.18 | A | |
| $19.90 | A | |
| $49.29 | A |
Be the first to know about important CAPS news, forecast changes, insider trades & much more!
CAPS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CAPS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CAPS is good value based on its book value relative to its share price (0.34x), compared to the US Biotechnology industry average (4.42x)
P/B vs Industry Valuation
CAPS's short-term assets ($16.71M) exceed its short-term liabilities ($14.66M)
Short-term Liabilities Financials
CAPS's short-term assets ($16.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more CAPS due diligence checks available for Premium users.
Valuation
CAPS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
4.42x
CAPS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CAPS's financial health
Profit margin
Revenue
$7.9M
Net Income
-$1.7M
Profit Margin
-30.8%
Assets to liabilities
Assets
$52.2M
Liabilities
$25.2M
Debt to equity
0.94
CAPS's short-term assets ($16.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAPS's short-term assets ($16.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAPS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
$4.0M
CAPS vs Biotech Stocks
Capstone Holding Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.